

For Immediate Release Washington, D.C. March 11, 2023

Contact: Jay Dolane

202-349-9650 ext. 800 membership@accmforum.org

American Council of Cannabis Medicine Announces with Sadness – Raphael Mechoulam, Israel's 'father of cannabis research, has died at the age of 92

Internationally known scientist helped ease the shift of medical cannabis out of counterculture and into the mainstream

Washington, DC — Today the American Council of Cannabis Medicine (ACCM) is saddened to announce the passing Raphael Mechoulam. The esteemed scientist who led groundbreaking research into psychoactive substance, with findings that helped ease its shift of medical cannabis out of counterculture and into the mainstream.

In 1994 Raphael Mechoulam was elected to be a member of the Israel Academy of Sciences and Humanities. Additionally, he was a founding member of the International Association for Cannabinoid Medicines and the International Cannabinoid Research Society.

During his tenure at the Hebrew University School of Pharmacy, Mechoulam and his research team isolated THC, the psychoactive component of cannabis, as well as cannabidiol, or CBD, an active ingredient in cannabis with many medicinal benefits.

"ACCM along with the American Medical Cannabis Community owe a great deal to Dr. Mechoulam." says, Scott Rancie, Vice-President of Members Services for ACCM. "His contributions have lead to untold scientific breakthroughs which have helped millions of people around the world. Our thoughts and prayers are with his family and friends."

He was an early leader in the study of the cannabinoid system in the body, which produces chemicals similar to THC which regulate appetite, manage pain and operate the immune system. Additionally, he discovered more about cannabis and its value in treating symptoms of other diseases, including cancers, and epilepsy.

Raphael Mechoulam was born in Bulgaria in 1930 and immigrated to Israel in 1949 with his family.

The American Council of Cannabis Medicine is the "Voice of American Medical Cannabis." ACCM represents America's medical-cannabis industry, which supports millions of U.S. jobs and is backed by a growing grassroots movement, supporting millions of beneficiaries. Members produce, process, and distribute medical cannabis through state-licensed programs, as well as, supporting companies, healthcare industry, physicians, researchers, health/wellness providers, insurance companies, systems, and patient advocacy groups. They participate in ACCM's 15 standing area-centric committees. ACCM was started in 2016 as a Capitol Hill working group and has developed into a mission driven 501c4. Our pressing objective is to facilitate legislation that advances medical cannabis at the federal level and improve state access.

Reach the American Council of Cannabis Medicine at 202-349-9650, or www.accmforum.org